Compare SPFI & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SPFI | ACRS |
|---|---|---|
| Founded | 1941 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 812.0M | 868.5M |
| IPO Year | 2019 | 2015 |
| Metric | SPFI | ACRS |
|---|---|---|
| Price | $41.75 | $5.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $46.00 | $10.20 |
| AVG Volume (30 Days) | 93.2K | ★ 2.4M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | 17.81 | ★ 69.01 |
| EPS | ★ 1.82 | N/A |
| Revenue | N/A | ★ $1,683,000.00 |
| Revenue This Year | $22.65 | N/A |
| Revenue Next Year | $9.40 | $4.24 |
| P/E Ratio | $22.87 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $35.34 | $1.74 |
| 52 Week High | $46.94 | $6.60 |
| Indicator | SPFI | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 27.98 | 41.16 |
| Support Level | $41.24 | $4.99 |
| Resistance Level | $42.58 | $5.83 |
| Average True Range (ATR) | 0.85 | 0.35 |
| MACD | -0.27 | -0.04 |
| Stochastic Oscillator | 3.50 | 24.68 |
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking. The majority of the company's revenues is derived from interest income and other sources, including loans, securities and derivatives.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.